Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to USD 22.7 billion in the first six months of 2025

Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors